Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

3

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Sphingosine 1-phosphate receptor Edg-1

3

Sphingosine 1-phosphate receptor Edg-3

3

Sphingosine 1-phosphate receptor Edg-6

3

Sphingosine 1-phosphate receptor Edg-8

3

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2010

3

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Multiple sclerosis

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

3

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Mitsubishi Pharma

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

3

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

3

DAILYMED

3

FDA UNII

3

PUBCHEM

3

RXCUI

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

IMMUNOSUPPRESSANTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

IMMUNOSUPPRESSANTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Selective immunosuppressants

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

2

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

FINGOLIMOD

3QN8BYN5QF

Export Data
Search for Structure

Status:

US Approved Rx (2021)

First approved in 2010

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Sphingosine 1-phosphate receptor Edg-8

Sphingosine 1-phosphate receptor Edg-6

Sphingosine 1-phosphate receptor Edg-3

Sphingosine 1-phosphate receptor Edg-1

Conditions:

Multiple sclerosis

Fingolimod (FTY720) is a sphingosine 1-phosphate receptor modulator indicated and approved for the treatment of relapsing-remitting multiple sclerosis. Fingolimod (trade name Gilenya, Novartis) is metabolized by sphingosine kinase to the active meta...

bolite, fingolimod-phosphate. Fingolimod-phosphate is a sphingosine 1-phosphate receptor modulator, and binds with high affinity to sphingosine 1-phosphate receptors 1, 3, 4, and 5. Fingolimod-phosphate blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which fingolimod exerts therapeutic effects in multiple sclerosis is unknown, but may involve reduction of lymphocyte migration into the central nervous system. Fingolimod was approved as a first-in-class, orally active drug for relapsing multiple sclerosis in 2010, and its applications in other disease conditions are currently under clinical trials.

FINGOLIMOD LAURYL SULFATE

J3HZQ9BE2S

Export Data
Search for Structure

Status:

US Approved Rx (2021)

First approved in 2010

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Sphingosine 1-phosphate receptor Edg-8

Sphingosine 1-phosphate receptor Edg-6

Sphingosine 1-phosphate receptor Edg-3

Sphingosine 1-phosphate receptor Edg-1

Conditions:

Multiple sclerosis

Fingolimod (FTY720) is a sphingosine 1-phosphate receptor modulator indicated and approved for the treatment of relapsing-remitting multiple sclerosis. Fingolimod (trade name Gilenya, Novartis) is metabolized by sphingosine kinase to the active meta...

bolite, fingolimod-phosphate. Fingolimod-phosphate is a sphingosine 1-phosphate receptor modulator, and binds with high affinity to sphingosine 1-phosphate receptors 1, 3, 4, and 5. Fingolimod-phosphate blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which fingolimod exerts therapeutic effects in multiple sclerosis is unknown, but may involve reduction of lymphocyte migration into the central nervous system. Fingolimod was approved as a first-in-class, orally active drug for relapsing multiple sclerosis in 2010, and its applications in other disease conditions are currently under clinical trials.

FINGOLIMOD HYDROCHLORIDE

G926EC510T

Export Data
Search for Structure

Status:

US Approved Rx (2021)

First approved in 2010

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Sphingosine 1-phosphate receptor Edg-8

Sphingosine 1-phosphate receptor Edg-6

Sphingosine 1-phosphate receptor Edg-3

Sphingosine 1-phosphate receptor Edg-1

Conditions:

Multiple sclerosis

Fingolimod (FTY720) is a sphingosine 1-phosphate receptor modulator indicated and approved for the treatment of relapsing-remitting multiple sclerosis. Fingolimod (trade name Gilenya, Novartis) is metabolized by sphingosine kinase to the active meta...

bolite, fingolimod-phosphate. Fingolimod-phosphate is a sphingosine 1-phosphate receptor modulator, and binds with high affinity to sphingosine 1-phosphate receptors 1, 3, 4, and 5. Fingolimod-phosphate blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which fingolimod exerts therapeutic effects in multiple sclerosis is unknown, but may involve reduction of lymphocyte migration into the central nervous system. Fingolimod was approved as a first-in-class, orally active drug for relapsing multiple sclerosis in 2010, and its applications in other disease conditions are currently under clinical trials.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1